000827882 001__ 827882
000827882 005__ 20210129225941.0
000827882 037__ $$aFZJ-2017-01965
000827882 1001_ $$0P:(DE-Juel1)166419$$aNeumaier, Bernd$$b0$$eCorresponding author$$ufzj
000827882 1112_ $$aThe First Palestinian International Conference On Peaceful Usage of Atomic Energy$$cPalestine Technical University in Tulkarm$$d2017-02-19 - 2017-02-20$$wPalestine
000827882 245__ $$aThe production of PET tracers for the diagnosis of oncological and neurological diseases
000827882 260__ $$c2017
000827882 3367_ $$033$$2EndNote$$aConference Paper
000827882 3367_ $$2DataCite$$aOther
000827882 3367_ $$2BibTeX$$aINPROCEEDINGS
000827882 3367_ $$2DRIVER$$aconferenceObject
000827882 3367_ $$2ORCID$$aLECTURE_SPEECH
000827882 3367_ $$0PUB:(DE-HGF)6$$2PUB:(DE-HGF)$$aConference Presentation$$bconf$$mconf$$s1488349612_7509$$xInvited
000827882 520__ $$aPositron emission tomography (PET) is a very sensitive method for the detection of pathophysiological processes on the molecular level. Radiotracers have to be designed, developed and synthesized capable to interact with molecular targets to exploit the potential of this method. Molecular targets mainly consist of enzymes or receptors overexpressed in diseased states like cancer or neurological disorders. The radiotracers specifically accumulate in these pathological regions indicating disease infiltration. These regions can be visualized by PET measurements delivering images of the 3D distribution of the radiotracer in vivo. The obtained PET scans deliver important diagnostic information and are essential for subsequent treatment planning.In this talk I will report about the design, radiosynthesis and application of PET tracers for diagnosis of neurological and oncological disorders.
000827882 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000827882 909CO $$ooai:juser.fz-juelich.de:827882$$pVDB
000827882 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b0$$kFZJ
000827882 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000827882 9141_ $$y2017
000827882 920__ $$lyes
000827882 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x0
000827882 980__ $$aconf
000827882 980__ $$aVDB
000827882 980__ $$aI:(DE-Juel1)INM-5-20090406
000827882 980__ $$aUNRESTRICTED